Biocon claimed that its expertise in fermentation technology and the team’s prior analytical development work with Fidaxomicin made it a suited manufacturer for Optimer’s product requirements.
Pedro Lichtinger, president and CEO of Optimer, said: “This long-term agreement with Biocon is an important step in establishing a stable supply of Fidaxomicin in the event it is approved.
“For the past five years, Biocon has been an important partner in our Fidaxomicin development program and we look forward to continuing the relationship.”
Kiran Mazumdar Shaw, CMD of Biocon Group, said: “Our partnership with Optimer is an acknowledgement of our manufacturing facilities.
“The close research and development partnership over the last five years has been a learning experience for all the Biocon staffers working on this project.”